Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: The prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study

Circulation

Volumn 110, Issue 11, 2004, Pages 1418-1423

  Boekholdt, S Matthijs ^a   Kuivenhoven, Jan Albert ^a   Wareham, Nicholas J ^c   Peters, Ron J G ^a   Jukema, J Wouter ^b   Luben, Robert ^e   Bingham, Sheila A ^d   Day, Nicholas E ^e   Kastelein, John J P ^a   Khaw, Kay Tee ^e,f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherosclerosis; Cholesterol; Coronary disease; Lipoproteins

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARRIER PROTEINS; CASE-CONTROL STUDIES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COHORT STUDIES; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS; FEMALE; GLYCOPROTEINS; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK; SMOKING; TRIGLYCERIDES;

EID: 4544230882     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000141730.65972.95     Document Type: Article

References (40)

1. The Scandinavian Simvastatin Survival Study Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20.536 high-risk individuals: a randomised placebo-controlled trial, Lancet. 2002;360:7-22.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane P, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707-714.
5. Miller NE, Thelle DS, Forde OH, Mjos OD. The Tromso heart-study: high-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet. 1977;1:965-968.
6. Gotto AM Jr. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103:2213-2218.
7. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem. 1995;64:235-257.
8. Freeman DJ, Packard CJ, Shepherd J, Gaffney D. Polymorphisms in the gene coding for cholesteryl ester transfer protein are related to plasma high-density lipoprotein cholesterol and transfer protein activity. Clin Sci. 1990;79:575-581.
9. Inazu AM, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
10. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705. in humans: a randomized phase II dose-response study. Circulation. 2002;105:2159-2165.
11. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, Bamberger MJ. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497.
12. Brousseau ME, Schaefer EJ, Wolfe ML, Bloeden L, Digenio AG, Clark RW, Mancuso J, Rader DJ. Effects of a potent inhibitor of cholesteryl ester transfer protein on plasma lipoproteins in patients with HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
13. Guerin M, Le Goff W, Lassel TS, van Tol A, Steiner G, Chapman MJ. Atherogenic role of elevated CE transfer from HDL to VLDL(I) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 2001;21:282-288.
14. Elchebly M, Porokow B, Pulcini T, Berthezene F, Ponsin G. Alterations in composition and concentration of lipoproteins and elevated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus (NIDDM). Atherosclerosis. 1996;123:93-101.
15. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in non-insulin-dependent diabetes mellitus. Atherosclerosis. 1993;104:69-77.
16. Hayek T, Masucci-Magoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR. Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene. J Clin Invest. 1995;96:2071-2074.
17. Hayek T, Azrolan N, Verdery RB, Walsh A, Chajek-Shaul T, Agellon LB, Tall AR, Breslow JL. Hypertriglyceridemia and cholesteryl ester transfer protein interact to dramatically alter high density lipoprotein levels, particle sizes, and metabolism: studies in transgenic mice. J Clin Invest. 1993;92:1143-1152.
18. Packard C, Caslake M, Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol. 2000;74:S17-S22.
19. Packard CJ, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997;17:3542-3556.
20. Barter PJ, Brewer HB Jr, Chapman MJ, Hennekens CH, Rader DJ, Tall AR. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol. 2003;23:160-167.
21. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort: European Prospective Investigation of Cancer. Br J Cancer. 1999;80:95-103.
22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
23. Bruins P, te Velthuis H, Yazdanbakhsh AP, Jansen PG, van Hardevelt FW, de Beaumont EM, Wildevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96:3542-3548.
24. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, Dallinga-Thie GM, DALI study group. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 2003;26:1216-1223.
25. Diggle PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford, UK: Oxford University Press; 1994.
26. Breslow NE, Day NE. Statistical Methods in Cancer Research. Volume 1: The Analysis of Case-Control Studies. Lyon, France: IARC Scientific Publications; 1980. Publication no. 32.
27. Liang KY, Beaty TH. Statistical designs for familial aggregation. Stat Methods Med Res. 2000;9:543-562.
28. De Grooth GJ, Smilde TJ, van Wissen S, Klerkx AH, Zwinderman AH, Fruchart JC, Kastelein JJ, Stalenhoef AF, Kuivenhoven JA. The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. Atherosclerosis. 2004;173:261-267.
29. Klerkx AH, De Grooth GJ, Zwinderman AH, Jukema JW, Kuivenhoven JA, Kastelein JJ. Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS). Eur J Clin Invest. 2004;34:21-28.
30. Kark JD, Sinnreich R, Leitersdorf E, Friedlander Y, Shpitzen S, Luc G. Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol. Atherosclerosis. 2000;151:509-518.
31. Bernard S, Moulin P, Lagrost L, Picard S, Elchebly M, Ponsin G, Chapuis F, Berthezene F. Association between plasma HDL-cholesterol concentration and Taq1B CETP gene polymorphism in non-insulin-dependent diabetes mellitus. J Lipid Res. 1998;39:59-65.
32. McPherson R, Mann CJ, Tall AR, Hogue M, Martin L, Milne RW, Marcel Y. Plasma concentrations of cholesteryl ester transfer protein in hyperlipoproteinemia: relation to cholesteryl ester transfer protein activity and other lipoprotein variables. Arterioscler Thromb. 1991:11:797-804.
33. Marcel Y, McPherson R, Hogue M, Czamecka H, Zawadzki Z, Weech PK, Whitlock ME, Tall AR, Milne RW. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipemic subjects. J Clin Invest. 1990;85:10-17.
34. Zhuang Y, Wang J, Qiang H, Li Y, Lui X, Li L, Chen G. Serum cholesteryl ester transfer protein concentrations in healthy Chinese subjects and cardio-cerebrovascular disease patients. Clin Chim Acta. 2001;305:19-25.
35. Boekholdt SM, Thompson JF. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res. 2003;44:1080-1093.
36. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med. 1990;323:1234-1238.
37. Ritsch A, Drexel H, Amann FW, Pfeihofer C, Patsch JR. Deficiency of cholesteryl ester transfer protein: description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol. 1997;17:3433-3441.
38. Arai T, Yamashita S, Sakai N, Hirano K, Okada S, Ishigami M, Maruyama T, Yamane M, Kobayashi H, Nozaki S, Funahashi T, Kameda-Takemura K, Nakajima N, Matsuzawa Y. A novel nonsense mutation (G181X) in the human cholesteryl ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res. 1996;37:2145-2150.
39. Curb JD, Abbott RD, Rodriguez BL, Masaki K, Chen R, Sharp DS, Tall AR. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res. 2004;45:948-953.
40. Noone E, Roche HM, Black I, Tully AM, Gibney MJ. Effect of postprandial lipaemia and Taq 1B polymorphism of the cholesteryl ester transfer protein (CETP) gene on CETP mass, activity, associated lipoproteins and plasma lipids. Br J Nutr. 2000;84:203-209.